[go: up one dir, main page]

UY28517A1 - Nueva combinación - Google Patents

Nueva combinación

Info

Publication number
UY28517A1
UY28517A1 UY28517A UY28517A UY28517A1 UY 28517 A1 UY28517 A1 UY 28517A1 UY 28517 A UY28517 A UY 28517A UY 28517 A UY28517 A UY 28517A UY 28517 A1 UY28517 A1 UY 28517A1
Authority
UY
Uruguay
Prior art keywords
new combination
active ingredient
sequentially
separately
treatment
Prior art date
Application number
UY28517A
Other languages
English (en)
Inventor
Nigel Boughton-Smith
Simon Cruwys
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY28517A1 publication Critical patent/UY28517A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención proporciona una composición farmacéutica, producto farmacéutico o kit que consta de un primer principio activo que es un antagonista del receptor P2X7 y un segundo principio activo el cual es un fármaco antiinflamatorio no esteroideo, para ser utilizados simultánea, secuencial o separadamente en el tratamiento de trastornos inflamatorios.
UY28517A 2003-09-18 2004-09-16 Nueva combinación UY28517A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0302488A SE0302488D0 (sv) 2003-09-18 2003-09-18 New combination

Publications (1)

Publication Number Publication Date
UY28517A1 true UY28517A1 (es) 2005-04-29

Family

ID=29212490

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28517A UY28517A1 (es) 2003-09-18 2004-09-16 Nueva combinación

Country Status (20)

Country Link
US (1) US20070082930A1 (es)
EP (1) EP1663224A1 (es)
JP (1) JP2007505900A (es)
KR (1) KR20060086942A (es)
CN (1) CN1859911A (es)
AR (1) AR045783A1 (es)
AU (1) AU2004271886B2 (es)
BR (1) BRPI0414558A (es)
CA (1) CA2538416A1 (es)
IL (1) IL173913A0 (es)
IS (1) IS8396A (es)
MX (1) MXPA06002722A (es)
NO (1) NO20061662L (es)
NZ (1) NZ545964A (es)
RU (1) RU2338556C2 (es)
SE (1) SE0302488D0 (es)
TW (1) TW200526199A (es)
UY (1) UY28517A1 (es)
WO (1) WO2005025571A1 (es)
ZA (1) ZA200602260B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
SE0300480D0 (sv) 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
WO2004105797A1 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
MXPA05012705A (es) * 2003-05-29 2006-02-08 Astrazeneca Ab Una composicion farmaceutica que comprende un antagonista del receptor p2x7 y un factor alfa de necrosis tumoral.
WO2004105796A1 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
SA05260265A (ar) * 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
SE0402925D0 (sv) * 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
WO2007008157A1 (en) * 2005-07-11 2007-01-18 Astrazeneca Ab New combination 2
US20080207577A1 (en) * 2005-07-11 2008-08-28 Astrazeneca Ab Combination I
JP2009527479A (ja) * 2006-02-17 2009-07-30 アバロン ファーマシューティカルズ，インコーポレイテッド ヒドロキシピペリジン誘導体とその使用
WO2009074518A1 (en) * 2007-12-12 2009-06-18 Glaxo Group Limited Combinations of prolinamide p2x7 modulators with further therapeutic agents
GB0724258D0 (en) * 2007-12-12 2008-01-30 Glaxo Group Ltd Novel combinations
GB0919594D0 (en) 2009-11-09 2009-12-23 Glaxo Group Ltd Compounds
DK2848256T3 (en) 2009-12-08 2019-03-04 Univ Vanderbilt Improved vein harvesting and autotransplantation methods and compositions
WO2011109833A2 (en) 2010-03-05 2011-09-09 President And Fellows Of Harvard College Induced dendritic cell compositions and uses thereof
WO2013082565A1 (en) * 2011-12-02 2013-06-06 Michael Kaleko Therapies for disorders of the cornea and conjunctiva
RU2702898C2 (ru) * 2014-09-10 2019-10-14 Гск Консьюмер Хелткер С.А. Композиции диклофенака натрия для местного применения

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471491A (en) * 1967-08-28 1969-10-07 Squibb & Sons Inc Adamantyl-s-triazines
US3464998A (en) * 1968-03-04 1969-09-02 Searle & Co Adamantyl esters and amides of pyridinecarboxylic acids
US4349552A (en) * 1978-10-30 1982-09-14 Fujisawa Pharmaceutical Company, Ltd. 5-Fluorouracil derivatives, and their pharmaceutical compositions
US4751292A (en) * 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
US5399564A (en) * 1991-09-03 1995-03-21 Dowelanco N-(4-pyridyl or 4-quinolinyl) arylacetamide and 4-(aralkoxy or aralkylamino) pyridine pesticides
JP2000510865A (ja) * 1996-05-20 2000-08-22 ダーウィン・ディスカバリー・リミテッド Ｔｎｆとｐｄｅ―ｉｖのインヒビターとしてのキノリンカルボキサミド
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704544D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
HUP0202214A3 (en) * 1999-04-09 2002-12-28 Astrazeneca Ab Adamantane derivatives, preparation and use thereof
SE9904505D0 (sv) * 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
TWI258462B (en) * 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
CA2394222A1 (en) * 1999-12-22 2001-06-28 Pharmacia Corporation Sustained-release formulation of a cyclooxygenase-2 inhibitor
GB0013737D0 (en) * 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
HRP20031080A2 (en) * 2001-07-02 2004-04-30 Akzo Nobel Nv Tetrahydroquinoline derivatives
PA8557501A1 (es) * 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
WO2003042190A1 (en) * 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
SE0103836D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Novel compounds
US6908939B2 (en) * 2001-12-21 2005-06-21 Galderma Research & Development S.N.C. Biaromatic ligand activators of PPARγ receptors
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
SE0300445D0 (sv) * 2003-02-18 2003-02-18 Astrazeneca Ab New combination
SE0300480D0 (sv) * 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
WO2004105796A1 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate
MXPA05012705A (es) * 2003-05-29 2006-02-08 Astrazeneca Ab Una composicion farmaceutica que comprende un antagonista del receptor p2x7 y un factor alfa de necrosis tumoral.
WO2004105797A1 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
NO20061662L (no) 2006-04-11
AU2004271886A1 (en) 2005-03-24
CA2538416A1 (en) 2005-03-24
WO2005025571A1 (en) 2005-03-24
RU2006112423A (ru) 2007-11-10
TW200526199A (en) 2005-08-16
AU2004271886B2 (en) 2008-03-20
ZA200602260B (en) 2007-07-25
MXPA06002722A (es) 2006-06-06
EP1663224A1 (en) 2006-06-07
IL173913A0 (en) 2006-07-05
NZ545964A (en) 2009-09-25
KR20060086942A (ko) 2006-08-01
RU2338556C2 (ru) 2008-11-20
US20070082930A1 (en) 2007-04-12
CN1859911A (zh) 2006-11-08
SE0302488D0 (sv) 2003-09-18
BRPI0414558A (pt) 2006-11-07
JP2007505900A (ja) 2007-03-15
AR045783A1 (es) 2005-11-16
IS8396A (is) 2006-04-03

Similar Documents

Publication Publication Date Title
UY28517A1 (es) Nueva combinación
CY1118179T1 (el) Φαρμακευτικη συνθεση
CL2011003266A1 (es) Compuestos derivados de imidazolidin-2-ona, con actividad inhibidora de 17alfa-hidroxilasa/liasa-c17,20; composicion farmaceutica que los comprende; y uso en el tratamiento de inflamacion o cancer, entre otras.
ECSP088763A (es) Nuevas combinaciones terapéuticas para el tratamiento de la depresión
CR8642A (es) Compuestos, composiciones farmaceuticas y metodos para su uso en el tratameinto de desordenes metabolicos
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
BRPI0816798A2 (pt) composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação
GT200600260A (es) Derivados de benzamida y usos relacionados con los mismos
CY1114933T1 (el) Στερεες φαρμακευτικες συνθεσεις σταθερης δοσης περιεχουσες ιρβεσαρτανη και αμλοδιπινη, η παρασκευη τους και η θεραπευτικη εφαρμογη τους
CL2007002875A1 (es) Composicion farmaceutica recubierta por una pelicula que comprende capecitabina y al menos un disgregante, util en el tratamiento del cancer para pacientes que tienen dificultad para tragar las formas de dosificacion solidas orales.
PA8579801A1 (es) Composiciones farmaceuticas de farmacos semiordenados y polimeros
CY1115384T1 (el) Αντι-φλεγμονωδης συνθεση
UY28335A1 (es) Nueva combinación
IL183481A0 (en) Antitumor combinations containing a vegf inhibitor and 5fu or one of its derivatives
AR054595A1 (es) Formulaciones/composiciones farmaceuticas de guanfacina apropiadas para forma de administracion diaria en una unica dosis
EP1940432A4 (en) ANTI-INFLAMMATORY COMPOSITIONS AND METHODS OF USE
AR052830A1 (es) Regimen de cladribina para tratar esclerosis multiple
EA201290378A1 (ru) Композиции, содержащие нестероидные противовоспалительные лекарственные средства
SE0203817D0 (sv) New composition
UY29989A1 (es) Composiciones farmacéuticas de agentes hipnoticos de accion corta en forma de liberación modificada y los procedimientos para preparar dichas formulaciones
DE602006012962D1 (de) Pharmazeutische Zubereitungen von Ciprofloxacin
CY1114028T1 (el) Φαρμακευτικες συνθεσεις για τη θεραπεια των ακροχορδωνων
AR065918A1 (es) Composiciones farmaceuticas sinergicas que comprenden la combinacion de un inhibidor de la enzina 5 alfa-reductasa y un antagonista de los receptores 1-adrenergicos
ECSP045142A (es) Combinacion farmaceutica
CL2007002762A1 (es) Composicion farmaceutica que comprende orlistat 60mg y rosuvastatina calcica equivalente a 5mg de rosuvastatina en una sola unidad de dosis, util para el tratamiento de la obesidad y la dislipidemia.

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20120322